Kepler Capital Markets restated their reduce rating on shares of GlaxoSmithKline (LON:GSK) in a report issued on Monday morning. The firm currently has a GBX 1,340 ($18.79) price objective on the stock.
Several other brokerages also recently commented on GSK. Deutsche Bank increased their price objective on GlaxoSmithKline from GBX 1,380 ($19.35) to GBX 1,440 ($20.19) and gave the stock a hold rating in a research note on Thursday, January 11th. set a GBX 1,925 ($26.99) price objective on GlaxoSmithKline and gave the stock a buy rating in a research note on Thursday, October 26th. Morgan Stanley lowered their price objective on GlaxoSmithKline from GBX 1,450 ($20.33) to GBX 1,400 ($19.63) and set an underweight rating for the company in a research note on Friday, December 1st. Berenberg Bank lowered their price objective on GlaxoSmithKline from GBX 1,835 ($25.73) to GBX 1,760 ($24.68) and set a buy rating for the company in a research note on Thursday, November 2nd. Finally, Goldman Sachs Group set a GBX 1,775 ($24.89) price objective on GlaxoSmithKline and gave the stock a buy rating in a research note on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of GBX 1,542.95 ($21.63).
GlaxoSmithKline (LON GSK) opened at GBX 1,303.80 ($18.28) on Monday. The stock has a market capitalization of $64,640.00 and a P/E ratio of 4,205.81. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($17.32) and a fifty-two week high of GBX 1,724.50 ($24.18).
In related news, insider Patrick Vallance sold 20,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Also, insider Sir Roy Anderson purchased 562 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were acquired at an average cost of GBX 1,278 ($17.92) per share, with a total value of £7,182.36 ($10,070.61). Insiders have purchased 581 shares of company stock valued at $743,284 over the last ninety days.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.